Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Net Income (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Net Income data on record, last reported at -$34.4 million in Q4 2022.

  • For Q4 2022, Net Income fell 129.4% year-over-year to -$34.4 million; the TTM value through Dec 2022 reached -$115.9 million, down 195.64%, while the annual FY2025 figure was -$158.3 million, 5.96% up from the prior year.
  • Net Income reached -$34.4 million in Q4 2022 per AVIR's latest filing, down from -$8.1 million in the prior quarter.
  • Across five years, Net Income topped out at $117.1 million in Q4 2021 and bottomed at -$42.1 million in Q1 2022.
  • Average Net Income over 3 years is -$472166.7, with a median of -$9.0 million recorded in 2020.
  • Peak YoY movement for Net Income: surged 870.14% in 2021, then tumbled 2136.06% in 2022.
  • A 3-year view of Net Income shows it stood at $20.7 million in 2020, then soared by 467.06% to $117.1 million in 2021, then plummeted by 129.4% to -$34.4 million in 2022.
  • Per Business Quant database, its latest 3 readings for Net Income were -$34.4 million in Q4 2022, -$8.1 million in Q3 2022, and -$31.3 million in Q2 2022.